Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 525-532

  Morita, Takanori ^a   Shibata, Kiyosumi ^a   Kikkawa, Fumitaka ^a   Kajiyama, Hiroaki ^a   Ino, Kazuhiko ^a   Mizutani, Shigehiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasion; Migration; Nude mice; Ovarian carcinoma; Oxytocin

Indexed keywords

GELATINASE A; OXYTOCIN; OXYTOCIN RECEPTOR; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MINIPUMP; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CADHERINS; CELL DIVISION; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OXYTOCIN; RECEPTORS, OXYTOCIN; TUMOR CELLS, CULTURED;

EID: 1542720299     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20017     Document Type: Article

References (21)

1. Russel JA, Leng G. Sex, parturition and motherhood without oxytocin? J Endocrinol 1998;157:343-59.
2. Elands J, de Kloet ER, De Wied D. Neurohypophyseal hormone receptors: relation to behavior. Prog Brain Res 1992;91:459-64.
3. Kimura T, Tanizawa O, Mori K, Brownstein M, Okayama H. Structure and expression of human oxytocin receptor. Nature 1992;356:526-9.
4. Cassoni P, Sapino A, Stella A, Bussolati G. Antiproliferative effect of oxytocin through specific oxytocin receptors in human neuroblastoma and astrocytoma cell lines. Exp Med Biol 1998;449:245-6.
5. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int J Cancer 1998;77:695-700.
6. Fay MJ, Du J, Longo KA, North WG. Oxytocin does not induce a rise in intracellular free calcium in human breast cancer cells. Res Commun Mol Pathol Pharmacol 1999;103:115-28.
7. Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G. Oxytocin receptors in human adenocarcinoma of the endometrium: presence and biological significance. J Pathol 2000;190:470-7.
8. Suzuki Y, Shibata K, Kikkawa F, Kajiyama H, Ino K, Nomura S, Tsujimoto M, Mizutani S. Possible role of placental leucine aminopeptidase (P-LAP) in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. Clin Cancer Res 2003;9:1528-34.
9. Pequeux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R, Geenen V, Legros JJ. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res 2002;62:4623-9.
10. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A, Bussolati G. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology 2001;142:1130-6.
11. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46 5-27.
12. Roszkowski P, Wronkowski Z, Szamborski J, Romejko M. Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol 1993;14:140-5.
13. Ozols RF. Management of advanced ovarian cancer consensus summary. Semin Oncol 2000;27:47-9.
14. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. J Am Med Assoc 1995;273:491-7.
15. Bookman MA. Biological therapy of ovarian cancer: current directions. Semin Oncol 1998;25:381-96.
16. Kaye SB, Eisenhauer EA, Hamilton TC. New non-cytotoxic approaches to ovarian cancer. Ann Oncol 1999;10:65-8.
17. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62:4656-62.
18. Bale TL, Dorsa DM. NGF, cyclic AMP, and phorbol esters regulate oxytocin receptor gene transcription in SK-N-SH and MCF7 cells. Brain Res Mol Brain Res 1998;53:130-7.
19. Luo J, Lubaroff DM, Hendrix MJ. Supression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999;59:3552-6.
20. Yano T, Yamasaki H. Regulation of cellular invasion and matrix metaloproteinase activity in HepG2 cell by connexin 26 transfection. Mol Carcinog 2001;31:101-9.
21. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitor of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003;63:2278-83.